Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Oncological Outcome Following Radical Prostatectomy in Patients with pT3 Prostate Cancer

Oncological Outcome Following Radical Prostatectomy in Patients with pT3 Prostate Cancer Background: The objective of this study was to retrospec-tively review the oncological outcome following radical prostatectomy (RP) in patients with pT3 prostate cancer. Patients and Methods: This study included a total of 101 patients who underwent RP and pelvic lymphadenectomy without neoadjuvant therapies and were subsequently diagnosed as having disease corresponding to pT3. In this series, bio-chemical recurrence was defined as a serum prostate-specific antigen (PSA) 0.2 ng/ml or greater on two consecutive measurements, and none of the patients received any adjuvant therapies until their serum PSA levels reached 0.4 ng/ml or greater. Results: The median age and preoperative serum PSA in these 101 patients were 69 years (range 53–79 years) and 11.7 ng/ml (range 2.6–58.1 ng/ml). Pathological examinations demonstrated that the pathological stage was pT3a and pT3b in 64 and 37, respectively, nodal status was pN0 and pN1 in 92 and 9, respectively, and Gleason score was 6, 7 and 8–10 in 20, 65 and 16, respectively. During the observation period (median 49 months; range 27–74 months), bio-chemical recurrence occurred in 35 of 101 patients (34.7%); however, none of the patients died of cancer progression. The 1-, 3- and 5-year biochemical recurrence-free survival rates were 83.2, 64.4 and 59.7%, respectively. Of several fac-tors examined, biochemical recurrence was significantly associated with pathological stage (pT3a vs. pT3b), Gleason score (6 or 7 vs. 8–10) and surgical margin status (negative vs. positive), among which pathological stage and surgical margin status appeared to be independent predictors of biochemical recurrence. Conclusion: These findings suggest that the oncological outcome of RP as mono-therapy for pT3 prostate cancer would be comparatively favorable; however, RP alone may not be sufficient in patients with seminal vesicle invasion and/or those with a positive surgical margin. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Urology Karger

Oncological Outcome Following Radical Prostatectomy in Patients with pT3 Prostate Cancer

Download PDF
5 pages

Loading next page...
 
/lp/karger/oncological-outcome-following-radical-prostatectomy-in-patients-with-NSMroTt0QL
Publisher
Karger
Copyright
© 2008 S. Karger AG, Basel
ISSN
1661-7649
eISSN
1661-7657
DOI
10.1159/000115413
Publisher site
See Article on Publisher Site

Abstract

Background: The objective of this study was to retrospec-tively review the oncological outcome following radical prostatectomy (RP) in patients with pT3 prostate cancer. Patients and Methods: This study included a total of 101 patients who underwent RP and pelvic lymphadenectomy without neoadjuvant therapies and were subsequently diagnosed as having disease corresponding to pT3. In this series, bio-chemical recurrence was defined as a serum prostate-specific antigen (PSA) 0.2 ng/ml or greater on two consecutive measurements, and none of the patients received any adjuvant therapies until their serum PSA levels reached 0.4 ng/ml or greater. Results: The median age and preoperative serum PSA in these 101 patients were 69 years (range 53–79 years) and 11.7 ng/ml (range 2.6–58.1 ng/ml). Pathological examinations demonstrated that the pathological stage was pT3a and pT3b in 64 and 37, respectively, nodal status was pN0 and pN1 in 92 and 9, respectively, and Gleason score was 6, 7 and 8–10 in 20, 65 and 16, respectively. During the observation period (median 49 months; range 27–74 months), bio-chemical recurrence occurred in 35 of 101 patients (34.7%); however, none of the patients died of cancer progression. The 1-, 3- and 5-year biochemical recurrence-free survival rates were 83.2, 64.4 and 59.7%, respectively. Of several fac-tors examined, biochemical recurrence was significantly associated with pathological stage (pT3a vs. pT3b), Gleason score (6 or 7 vs. 8–10) and surgical margin status (negative vs. positive), among which pathological stage and surgical margin status appeared to be independent predictors of biochemical recurrence. Conclusion: These findings suggest that the oncological outcome of RP as mono-therapy for pT3 prostate cancer would be comparatively favorable; however, RP alone may not be sufficient in patients with seminal vesicle invasion and/or those with a positive surgical margin.

Journal

Current Urology – Karger

Published: Jan 1, 2008

Keywords: Prostate cancer; Radical prostatectomy; pT3; Biochemical recurrence

There are no references for this article.